Company | Price d* | Change d* | Volume, Avg. k, d* | Market Cap. d* | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding d* | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 13,671.73 | 833.94 | 205.45 | -200.00 | 32.19 | 0.02 | 13.4593 | -0.42 | -108.9858 | -2,428.2283 | -9.34 | -8.82 | 799.1504 | - - | ||
Maximum | - - | - - | - - | 593,913.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.94 | 1,336.3467 | 6.70 | 300.5100 | 8,534.8500 | 38.40 | 835.37 | 6,156.2100 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -1,175.00 | -56,335.00 | -1,185.00 | 0.00 | -164.8536 | -8.99 | -10,177.5800 | -144,478.0000 | -155.91 | -1,263.79 | 0.0700 | - - | ||
Amphastar Pharmaceuticals, Inc. AMPH | 50.11 | 0.33 0.66% | 25 vs. 392 | 2,439.00 | 171.00 | 43.00 | 46.00 | 452.00 | 0.9000 | 12.1264 | 0.00 | 50.80 | 25.13 | 6.42 | 2.74 | 168.56 | 48.00 | ||
Alkermes plc ALKS | 28.14 | 0.31 1.11% | 96 vs. 1,784 | 4,633.00 | 350.00 | 36.00 | 12.00 | -1,306.00 | 0.2200 | 31.0625 | 0.00 | 82.56 | 10.51 | 2.94 | 1.73 | 231.41 | 164.00 | ||
Neurocrine Biosciences, Inc. NBIX | 122.31 | 2.46 2.06% | 49 vs. 925 | 12,350.00 | 515.00 | 43.00 | 119.00 | -113.00 | 0.4300 | 81.2772 | 0.00 | 97.52 | 8.42 | 1.82 | 1.25 | 233.03 | 100.00 | ||
Intra-Cellular Therapies, Inc. ITCI | 75.79 | 1.09 1.46% | 43 vs. 944 | 8,008.00 | 144.00 | -15.00 | -34.00 | -1,632.00 | -0.1600 | -108.4422 | 0.00 | 93.17 | -10.52 | -2.54 | -2.04 | 451.43 | 105.00 |